脑低灌注在多发性硬化中的作用(ROCHIMS):波生坦概念验证随机对照试验研究方案
ROCHIMS是一项概念验证双盲随机对照试验,复发缓解型多发性硬化患者接受波生坦62.5 mg或匹配安慰剂每日两次、持续28±2天。主要结局为半卵圆中心正常表现白质中N-乙酰天冬氨酸的变化,以评估恢复脑血流能否改善轴突代谢。
要点
- 多发性硬化正常表现白质存在全脑血流受损,可能与星形胶质细胞内皮素-1过表达有关。
- 单次62.5 mg波生坦已在多发性硬化患者中显示短期脑血流恢复。
- 本试验以半卵圆中心正常表现白质N-乙酰天冬氨酸变化为主要结局。
核心结论
- 作者假设恢复多发性硬化患者的脑低灌注可改善轴突代谢,并可能早期检测到对疲劳和认知功能障碍的效应。
研究设计与样本
- ROCHIMS为概念验证双盲随机对照试验,复发缓解型多发性硬化患者接受波生坦62.5 mg或匹配安慰剂每日两次、持续28±2天。
- 基线和治疗结束时进行临床评估和脑磁共振成像。
主要发现
- 基于既往工作,预期波生坦治疗个体全脑脑血流增加。
- 主要结局指标为半卵圆中心正常表现白质中N-乙酰天冬氨酸的变化,该指标是区域轴突线粒体活动的标志物。
- 其他关注参数包括疲劳、认知、运动功能、抑郁和脑容量的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Axonal degeneration is related to long-term disability in patients with multiple sclerosis (MS). The underlying mechanism remains ill understood but appears to involve axonal energetic dysfunction. A globally impaired cerebral blood flow (CBF) has been observed in the normal-appearing white matter (NAWM) of patients with MS, which is probably related to astrocytic overexpression of endothelin-1 (ET-1). Cerebral hypoperfusion has been associated with reduced mitochondrial activity and disabling symptoms (e.g. fatigue and cognitive decline) of MS. Countering this process could therefore be beneficial in the disease course. Short-term CBF restoration with a single 62.5-mg dose of the ET-1 receptor antagonist bosentan has already been demonstrated in patients with MS. METHODS: The ROCHIMS study is a proof-of-concept double-blind randomized clinical trial in which patients with relapsing-remitting MS will receive either 62.5 mg bosentan or matching placebo twice daily during 28 ± 2 days. Clinical evaluation and brain magnetic resonance imaging (MRI) will be performed at baseline and treatment termination. Based on previous work, we expect a global increase of CBF in the individuals treated with bosentan. The primary outcome measure is the change of N-acetyl aspartate in centrum semiovale NAWM, which is a marker of regional axonal mitochondrial activity. Other parameters of interest include changes in fatigue, cognition, motor function, depression, and brain volume. DISCUSSION: We hypothesize that restoring cerebral hypoperfusion in MS patients improves axonal metabolism. Early positive effects on fatigue and cognitive dysfunction related to MS might additionally be detected. There is a medical need for drugs that can slow down the progressive axonal degeneration in MS, making this an important topic of interest. TRIAL REGISTRATION: Clinical Trials Register, EudraCT 2017-001253-13 . Registered on 15 February 2018.
引用
- Hostenbach S, Pauwels A, Michiels V, et al. Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan. Trials. 2019. PMID: 30871594. doi:10.1186/s13063-019-3252-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。